Artisan Partners Limited Partnership Boosts Stock Holdings in Medtronic PLC $MDT

Artisan Partners Limited Partnership lifted its stake in Medtronic PLC (NYSE:MDT) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,234,550 shares of the medical technology company’s stock after buying an additional 31,314 shares during the period. Artisan Partners Limited Partnership owned approximately 0.10% of Medtronic worth $117,579,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of MDT. Corundum Trust Company INC purchased a new position in Medtronic in the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic in the third quarter worth $29,000. Delos Wealth Advisors LLC bought a new stake in Medtronic during the 2nd quarter valued at $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic in the 3rd quarter worth $33,000. Finally, Tripletail Wealth Management LLC purchased a new position in shares of Medtronic in the third quarter valued at about $34,000. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Up 0.6%

NYSE MDT opened at $97.60 on Friday. The firm has a market capitalization of $125.31 billion, a PE ratio of 27.19, a P/E/G ratio of 2.44 and a beta of 0.71. The stock’s 50 day moving average is $98.93 and its 200 day moving average is $96.86. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is presently 79.11%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. CICC Research started coverage on shares of Medtronic in a report on Friday, January 30th. They set an “outperform” rating for the company. JPMorgan Chase & Co. cut their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Mizuho raised Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Leerink Partners dropped their price target on Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research note on Wednesday, February 18th. Finally, Robert W. Baird cut their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $110.84.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).